Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Durability of Heterologous and Homologous COVID-19 Vaccine Boosts
Chen Tan, Ai‐ris Y. Collier, Jingyou Yu, et al.
JAMA Network Open (2022) Vol. 5, Iss. 8, pp. e2226335-e2226335
Open Access | Times Cited: 55

Showing 26-50 of 55 citing articles:

Pivoting to protein: the immunogenicity and safety of protein-based NVX-CoV2373 as a heterologous booster for inactivated and viral vector COVID-19 vaccines
Anthony M. Marchese, Raj Kalkeri, Muruga Vadivale, et al.
Expert Review of Vaccines (2023) Vol. 22, Iss. 1, pp. 620-628
Open Access | Times Cited: 5
Mechanistic models of humoral kinetics following COVID-19 vaccination
Daniel Stocks, Amy Thomas, Adam Finn, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Long-term levels of protection of different types of immunity against the Omicron variant: a rapid literature review
Sabina Rodriguez Velásquez, Loza Biru, Sandrine Marie Hakiza, et al.
Schweizerische medizinische Wochenschrift (2024) Vol. 154, Iss. 5, pp. 3732-3732
Open Access | Times Cited: 1
Selective IgA Deficiency May Be an Underrecognized Risk Factor for Severe COVID-19
Rohan Ameratunga, Euphemia Leung, See‐Tarn Woon, et al.
The Journal of Allergy and Clinical Immunology In Practice (2022) Vol. 11, Iss. 1, pp. 181-186
Open Access | Times Cited: 8
Immunogenicity and safety of NVX-CoV2373 as a booster: A phase 3 randomized clinical trial in adults
Fritz Raiser, Matthew Davis, Jeffrey Adelglass, et al.
Vaccine (2023) Vol. 41, Iss. 41, pp. 5965-5973
Open Access | Times Cited: 4
Effectiveness of the Booster Dose in Protecting against COVID-19, Colombia 2022
Jubby Marcela Gálvez, Ángela María Pinzón-Rondón, Henry Mauricio Chaparro-Solano, et al.
Vaccines (2023) Vol. 11, Iss. 9, pp. 1461-1461
Open Access | Times Cited: 4
Heterogeneous hybrid immunity against Omicron variant JN.1 at 11 months following breakthrough infection
Xuan He, Jiajing Jiang, Li Guo, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Heterologous Booster Dose with CORBEVAX following Primary Vaccination with COVISHIELD Enhances Protection against SARS-CoV-2
J. Shashidhar, Apoorva Munigela, Mitnala Sasikala, et al.
Vaccines (2022) Vol. 10, Iss. 12, pp. 2146-2146
Open Access | Times Cited: 7
Strong SARS-CoV-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Hematopoietic Stem Cell Recipients
Béatrice Clémenceau, Amandine Le Bourgeois, Thierry Guillaume, et al.
Cells (2022) Vol. 11, Iss. 19, pp. 3010-3010
Open Access | Times Cited: 6
Effectiveness of the Booster Dose in Protecting against COVID 19, Colombia 2022
Jubby Marcela Gálvez, Ángela María Pinzón-Rondón, Henry Mauricio Chaparro-Solano, et al.
(2023)
Open Access | Times Cited: 3
Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection
Thandeka Moyo-Gwete, Simone I. Richardson, Roanne Keeton, et al.
PLoS Pathogens (2023) Vol. 19, Iss. 11, pp. e1011772-e1011772
Open Access | Times Cited: 3
Augmenting Vaccine Efficacy against Delta Variant with ‘Mycobacterium-w’-Mediated Modulation of NK-ADCC and TLR-MYD88 Pathways
Sarita Rani Jaiswal, Ashraf Saifullah, Jaganath Arunachalam, et al.
Vaccines (2023) Vol. 11, Iss. 2, pp. 328-328
Open Access | Times Cited: 2
Assessment of Anti-SARS-CoV-2 antibody levels among university students vaccinated with different COVID-19 primary and booster doses — fall 2021, Wisconsin
Peter M. DeJonge, Anastasia S. Lambrou, Hannah E. Segaloff, et al.
BMC Infectious Diseases (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 2
Fc mediated pan-sarbecovirus protection after alphavirus vector vaccination
Lily E. Adams, Sarah R. Leist, Kenneth H. Dinnon, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 4
Durability of the Effectiveness of Heterologous COVID-19 Vaccine Regimens in Thailand: Retrospective Cohort Study Using National Registration Data
Ponlagrit Kumwichar, Chittawan Poonsiri, Siobhan Botwright, et al.
JMIR Public Health and Surveillance (2024) Vol. 10, pp. e48255-e48255
Open Access
Safety, Effectiveness and Immunogenicity of heterologous mRNA-1273 Boost after Prime with Ad26.COV2.S among Healthcare Workers in South Africa: the single-arm, open-label, Phase 3 SHERPA Study
Nigel Garrett, Tarylee Reddy, Nonhlanhla Yende‐Zuma, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Vaccination against COVID-19 in a post-pandemic era
Felippe Lazar Neto, Adrián Ceccato, Otávio T. Ranzani
European Respiratory Society eBooks (2024)
Closed Access
Safety, effectiveness and immunogenicity of heterologous mRNA-1273 boost after prime with Ad26.COV2.S among healthcare workers in South Africa: The single-arm, open-label, phase 3 SHERPA study
Nigel Garrett, Tarylee Reddy, Nonhlanhla Yende‐Zuma, et al.
PLOS Global Public Health (2024) Vol. 4, Iss. 12, pp. e0003260-e0003260
Open Access
Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection
Thandeka Moyo-Gwete, Simone I. Richardson, Roanne Keeton, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 1
Immunogenicity and safety of NVX-CoV2373 as a homologous or heterologous booster: A phase 3 randomized clinical trial in adults
Fritz Raiser, Matthew Davis, Jeffrey Adelglass, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 1
Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults
Sue Ann Costa Clemens, Natalie G. Marchevsky, Sarah Kelly, et al.
Human Vaccines & Immunotherapeutics (2023) Vol. 19, Iss. 2
Open Access | Times Cited: 1
Immunologic response and seroconversion following third-dose COVID-19 vaccination in solid organ transplant recipients: A meta-analysis
Richard Christian Suteja, Albert Salim, I Putu Divanaya Suryanov, et al.
Transplant Immunology (2023) Vol. 80, pp. 101902-101902
Closed Access | Times Cited: 1
Humoral Immune Response to Messenger RNA Coronavirus Disease 2019 Vaccination Among Children Aged 5–11 Years in a Multisite Prospective Cohort Study, September 2021–September 2022
Zoë L. Lyski, Cynthia Porter, Jennifer L. Uhrlaub, et al.
Open Forum Infectious Diseases (2023) Vol. 10, Iss. 8
Open Access | Times Cited: 1
The 6-Month Antibody Durability of Heterologous Convidecia Plus CoronaVac and Homologous CoronaVac Immunizations in People Aged 18–59 Years and over 60 Years Based on Two Randomized Controlled Trials in China
Hu-Dachuan Jiang, Pengfei Jin, Xiling Guo, et al.
Vaccines (2023) Vol. 11, Iss. 12, pp. 1815-1815
Open Access | Times Cited: 1
Protection of homologous and heterologous boosters after primary schemes of rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV during the Omicron outbreak in adults of 50 years and older in Argentina: a test-negative case-control study
Soledad González, Santiago Olszevicki, Alejandra Gaiano, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 2

Scroll to top